No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Diagnostics & Research
Guangzhou Wondfo Biotech Co.,Ltd operates as a biotechnology enterprise, specializing in the research, development, production, and distribution of point-of-care testing (POCT) products. The company additionally provides rapid diagnostic tools and comprehensive solutions for managing chronic diseases. Its product catalog features an array of rapid test kits, addressing conditions like COVID-19, substance abuse, certain cancers, infectious diseases, fertility, and sexually transmitted infections. Furthermore, Wondfo Biotech offers immunofluorescence devices designed to identify cardiovascular conditions, inflammatory markers, kidney damage, hormonal imbalances (including sex hormones and thyroid function), diabetes, and specific tumor indicators. The firm also supplies analytical instruments, such as blood gas, optical coagulation, and dry chemistry analyzers. Established in 1992, the company's main operations are based in Guangzhou, China.
www.wondfo.comNo one on the platform currently holds 300482.SZ.
No tracked institution reports a position in 300482.SZ as of their last filing.
No one on the platform has traded 300482.SZ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | -31.9% | -5.8% | ||||
| Profit Margin % | -3.0% | 14.6% | 17.8% | |||
| Free Cash Flow Margin % | 7.6% | 6.2% | 7.6% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $2.0B | -14.7% | $0.57 | $0.46–$0.68 | — | 4 |
| 2027 | $2.2B | +11.3% | $0.66 | $0.50–$0.76 | — | 4 |
| 2028 | $2.4B | +10.2% | $0.78 | $0.63–$0.92 | — | 3 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| $11.30 |
| +1.07% |
| $6.6B |
| — |
| 300685.SZAmoy Diagnostics Co., Ltd. | $17.31 | +1.76% | $6.8B | — |
| 600422.SSKPC Pharmaceuticals, Inc. | $8.14 | +0.49% | $6.2B | — |
Source: Financial Modeling Prep · peers by sector/industry